• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

IMiDs in Relapsed/Refractory Multiple Myeloma

home / insights / imids-in-relapsed-refractory-multiple-myeloma

Two experts discuss the role immunomodulatory drugs (IMiDs) play in the current treatment landscape for relapsed/refractory multiple myeloma and how they can be used effectively.

© 2024 MJH Life Sciences
All rights reserved.